Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAC1 | P63000 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | DOT1L | Q8TEK3 | 6/20 | 0.61 |
| ▸ | TERT | O14746 | 7/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.44 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3511071 | 0.99 | RAC1 (1.00) | RAC1MAPTDOT1LTERTKCNH3 | |
| SCHEMBL13868216 | 0.90 | RAC1 (0.81) | RAC1MAPTDOT1LTERTKCNH3 | |
| SCHEMBL14825396 | 0.89 | RAC1 (0.80) | RAC1MAPTDOT1LTERT | |
| SCHEMBL3389936 | 0.89 | RAC1 (0.79) | RAC1MAPTDOT1LKCNH3CACNA2D1 | |
| Ammonia Solution, Strong SCHEMBL3727545 | 0.82 | RAC1 (0.69) | RAC1MAPTKCNH3CACNA2D1CCR4 | |
| SCHEMBL3389537 | 0.81 | RAC1 (0.68) | RAC1MAPTTERTKCNH3CACNA2D1 | |
| SCHEMBL2639299 | 0.78 | RAC1 (0.63) | RAC1MAPTDOT1LTERTCCR4 | |
| Hydrochloric Acid SCHEMBL17022810 | 0.77 | RAC1 (0.64) | RAC1MAPTDOT1LTERTCCR4 | |
| SCHEMBL3392632 | 0.72 | RAC1 (0.58) | RAC1MAPTKCNH3CACNA2D1CCR4 | |
| SCHEMBL3725741 | 0.72 | RAC1 (0.55) | RAC1MAPTKCNH3CACNA2D1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4691041-B2 | — | — | 2011-06-01 | — | — | JP | claimed |
| US-7612080-B2 | GTPase inhibitors and use thereof for controlling platelet hyperactivity | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2009-11-03 | — | — | US | claimed |
| US-7517890-B2 | GTPase inhibitors and methods of use | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2009-04-14 | — | — | US | claimed |
| EP-1920048-A2 | GTPASE INHIBITORS AND METHODS OF USE AND CRYSTAL STRUCTURE OF RAC-1 GTPASE | Children's Hospital Medical Center (US) | 2008-05-14 | — | — | EP | claimed |
| EP-1814553-A2 | GTPASE INHIBITORS AND USE THEREOF FOR CONTROLLING PLATELET HYPERACTIVITY | Children's Hospital Medical Center (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2007016539-A2 | GTPASE INHIBITORS AND METHODS OF USE AND CRYSTAL STRUCTURE OF RAC-1 GTPASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-02-08 | — | — | WO | claimed |
| EP-1691812-A1 | GTPASE INHIBITORS AND METHODS OF USE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2006-08-23 | — | — | EP | claimed |
| US-20060135542-A1 | GTPase inhibitors and use thereof for controlling platelet hyperactivity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-22 | — | — | US | claimed |
| WO-2006055833-A2 | GTPASE INHIBITORS AND USE THEREOF FOR CONTROLLING PLATELET HYPERACTIVITY | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060004032-A1 | GTPase inhibitors and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-05 | — | — | US | claimed |
| WO-2005051392-A1 | GTPASE INHIBITORS AND METHODS OF USE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2005-06-09 | — | — | WO | claimed |
| US-20240307414-A1 | METHODS AND MATERIALS FOR TREATING PROSTATE CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-09-19 | — | — | US | disclosed |
| WO-2024091473-A1 | TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS | REVERE PHARMACEUTICALS (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024018469-A1 | A COMBINATION FOR TREATING A RETINAL DISEASE | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2024-01-25 | — | — | WO | disclosed |
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-11-02 | — | — | US | disclosed |
| US-20060135542-A1 | GTPase inhibitors and use thereof for controlling platelet hyperactivity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-22 | — | — | US | disclosed |
| WO-2006055833-A2 | GTPASE INHIBITORS AND USE THEREOF FOR CONTROLLING PLATELET HYPERACTIVITY | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060004032-A1 | GTPase inhibitors and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-05 | — | — | US | disclosed |
| WO-2005051392-A1 | GTPASE INHIBITORS AND METHODS OF USE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051392-A1 | GTPASE INHIBITORS AND METHODS OF USE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346879-A1 | COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS | RAB5IF, CLTB, TBK1 | RAC1 320/4885MAPT 1926/4885DOT1L 3360/4885 |
| US-20060135542-A1 | GTPase inhibitors and use thereof for controlling platelet hyperactivity | ARHGDIB, ARHGEF2, RAC1 | RAC1 3/4885MAPT 3929/4885DOT1L 2731/4885 |
| US-20060004032-A1 | GTPase inhibitors and methods of use | RAC1, RAC2, ARHGDIB | RAC1 1/4885MAPT 2697/4885DOT1L 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.